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A B S T R A C T
Healthcare acquired infections (HAI's) are a worldwide problem that can be exacerbated by surgery and the
implantation of polymeric medical devices. The use of polymer based medical devices which incorporate anti-
microbial strategies are now becoming an increasingly routine way of trying to prevent the potential for reduce
chronic infection and device failure. There are a wide range of potential antimicrobial agents currently being
incorporated into such polymers. However, it is diﬃcult to determine which antimicrobial agent provides the
greatest infection control. The economics of replacing current methods with impregnated polymer materials
further complicates matters. It has been suggested that the use of a holistic system wide approach should to be
developed around the implantation of medical devices which minimises the potential risk of infection. However,
the use of such diﬀerent approaches is still being developed. The control of such infections is important for
individual patient health and the economic implications for healthcare services.
1. Introduction
The association between microbial contamination and its role in the
potential to lead to pathogenic infection is well established (Ashbolt,
2004; Weber and Rutala, 2013; Kenters et al., 2015; Marra et al., 2017).
Healthcare acquired infections (HAI's) have become a major problem
with 2011 UK data suggesting that an overall 6.5% of NHS patients
have contracted a HAI. In the USA, the Centers for Disease Control
(CDC) reported a 4% likelihood of a patient contracting a HAI
throughout the duration of their hospital care (Centers for Disease
Control and Prevention, 2016).
Whilst almost all pathogens have the potential to become proble-
matic in hospitalised patients, the aetiology of most HAI's can be traced
back to a few bacterial species namely Staphylococcus aureus,
Pseudomonas aeruginosa, Escherichia coli, coagulase-negative staphylo-
cocci (CoNS) (predominantly S. epidermidis) and Enterococcus spp.
(predominately E. faecalis and E. faecium) (Martin et al., 1989; Emori
and Gaynes, 1993; Bereket et al., 2012). For indwelling devices, it is
often the location of the implant that dictates the most likely colonising
pathogen. For instance, vascular implants are more likely to experience
colonisation by coagulase-negative staphylococci and S. aureus, while E.
coli and Enterococcus sp. were most likely to be recovered from urinary
devices (Zhang et al., 2017). Potentially, this could make the task of
controlling nosocomial infections sound relatively straightforward.
However, the complexity of the bacterial cell and surface interface and
the ever increasing prevalence of antimicrobial resistant pathogens
(AMR) makes controlling such scenarios complicated and has led to
global concerns (Jones, 2001; Andersson and Hughes, 2010;
Laxminarayan et al., 2013).
Today, microbial resistance to nearly every current antibiotic has
been observed (Jones, 2001). This was highlighted by the reporting of
over 2 million AMR infections in the USA in 2013 alone. It has been
estimated that in the last 20 years, 6%–14% of all hospitalised patients
have developed a nosocomial infection associated with either an in-
ternal or partially internal medical device (Malheiro and Simões, 2017).
2. Uses, properties and types of indwelling polymeric medical
implants
The use of synthetic polymers in a medical capacity began with the
introduction of polypropylene (PP), nylon, and polyester sutures in
World War II (Gilbert, 1999; Dumitriu, 2001). Since this beginning,
many common and vital procedures now rely on the use of polymers,
including, catheters (epidural, urinary and vascular), cardiovascular
devices (pacemakers, heart valves and left ventricular devices) and
stents (vascular and urinary). Additionally, the subsequent decades
have also seen many more polymers ﬁnd application within the clinical
setting, however, a few still account for the majority of uses. These
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include polyvinyl chloride (PVC), polyoleﬁns (polyethylene (PE),
polypropylene (PP)), polystyrene (PS), polyurethane (PU) and silicon
(Lambert et al., 2001; Gunatillake and Adhikari, 2016).
The use of a range of polymers has continued to grow within the
medical ﬁeld due to the materials diverse malleability, chemical
properties, robust functionality, simplicity of production and low cost
of raw materials (Lambert et al., 2001; Maitz, 2015). In addition, for
indwelling devices, more advanced mechanical properties can also be
exploited. For example, there has been the development of ‘smart’
polymers that can react to the use of pH, temperature, magnetic ﬁeld or
light for use in speciﬁc applications (Aguilar and Roman, 2014; Weems
et al., 2017).
3. Biological mechanisms of device failure and the development of
infection risk
Microbial contamination is often cited as a common reason for the
failure of indwelling medical device due to bioﬁlm formation, en-
crustation and blockage (Veerachamy et al., 2014). A bioﬁlm can be
described as a consortium of irreversibly surface associated in-
dependent cells with an extraordinary degree of organisation, em-
bedded in a predominantly extracellular polysaccharide and water
(80–90%) matrix (Donlan, 2002; Azevedo et al., 2017b; Stoica et al.,
2017).
3.1. Bioﬁlm formation
The major concern with microbial colonisation on biomaterial sur-
faces is the development of bioﬁlms which due to their recalcitrant
nature, can cause serious infection and device malfunction and removal
(Mermel et al., 2009). Bioﬁlms are now known to be responsible for
65% of nosocomial infections (Malheiro and Simões, 2017). The process
of microbial colonisation and bioﬁlm formation starts by the con-
ditioning of the surface. In the case of indwelling devices this process
occurs almost instantaneously after implantation. For venous implants,
this process is facilitated by the deposition of organic macromolecules
which form a conditioning ﬁlm such as pyruvate, glucose and ﬁ-
brinogen. For urinary implants, the conditioning ﬁlm is compiled of
proteins (e.g. Tamm-Horsfall protein), electrolytes (e.g. magnesium and
calcium ions), and other organic molecules (Murga et al., 2001;
Trautner and Darouiche, 2004; Nicolle, 2014). Following the attach-
ment of a conditioning ﬁlm (Fig. 1), the attachment of phenotypic
pioneer species facilitates surface colonisation of bacteria and
development of the bioﬁlm (Fig. 1). These microcolonies allow for the
attachment of further species which can result in a multi-layered,
multispecies bioﬁlm. The complex architecture displayed by bioﬁlms
allows for the coexistence of a vastly diﬀerent, but cohesive multi-
cellular ecosystem with cooperative and antagonistic interactions,
which may include a variety of pathogenic microbes (Flemming et al.,
2016a; Bowen et al., 2017). However, it is interesting to note that in
some scenarios, for example hip replacements, infection is often only
due to single bacterial species (Tunney et al., 1998).
3.2. Bioﬁlm dispersal
Bioﬁlm dispersal is the ﬁnal stage of bioﬁlm development and re-
sults in the colonisation of new locations, posing a signiﬁcant threat to
the host. Dispersal is a highly regulated process during which some
microbes undergo a phenotypic transition from a relatively slow
growing collective, to an often highly motile individual and/or multi-
cellular aggregate (Petrova and Sauer, 2016). The inter- or intra-species
release of quorum-sensing (QS) molecules, such as acylhomoserine
lactones, diﬀusible fatty acids and peptides, can inﬂuence the dispersal
rate (Petrova and Sauer, 2016). Interspecies QS has also been reported,
with many organisms being able to act or initiate speciﬁc behaviour in
other microbial species. This can be especially signiﬁcant in clinically
important pathogens and the onset of co-infections (Silvester et al.,
2017). More recently, the discovery that bioﬁlms can communicate
using long range electrical signals has raised questions about how
novel, potential mechanisms in bioﬁlms cause infection and enhance
the development of AMR (Humphries et al., 2017; Liu et al., 2017).
3.3. Bioﬁlm antimicrobial resistance mechanisms
Bioﬁlms can often be found to be up to a thousand times more re-
calcitrant towards antimicrobials. These high levels of resistance can be
acquired by utilising a wide variety of mechanisms, and often multiple
mechanisms are employed in conjunction (Fig. 2). The architecture of
the bioﬁlm is not uniform (Fig. 3) and will be dependent on the mi-
crobial species involved and environmental conditions (Whitehead and
Verran, 2015).
3.4. Extracellular polymeric substance (EPS)
Exopolymeric substances (EPS) are composed of glycoproteins and
polysaccharides and their structure provides a mechanism for survival
in host conditions, as well as a means to avoid the host immune re-
sponse (Fig. 4). In addition, EPS secreted by bioﬁlms produces elec-
trostatic forces that can provide the structural integrity for bioﬁlm
aggregation and which can also enable surface adhesion (Flemming
et al., 2016a,b). Whilst for many years the physical barrier to diﬀusion
oﬀered by EPS was proposed as the major resistance mechanism
(Dufour et al., 2010; Singh et al., 2016) other research has suggested
this may only play a minimal role in some instances (Stone et al., 2002;
Stewart et al., 2009; Daddi Oubekka et al., 2012; Hall and Mah, 2017).
However, antimicrobial degrading/modifying enzymes and eDNA im-
mobilised within the polysaccharide matrix may provide a chemical
barrier to the diﬀusion of antimicrobials and thus drug susceptibility
(Dufour et al., 2010; Murakami et al., 2017).
3.5. Eﬄux pumps
Eﬄux pumps are found across all bacterial species and act as a
major method of antimicrobial resistance. They are deﬁned as a me-
chanism of recognition and expulsion of toxic compounds from within
the cell to an external substrate before they reach their targets (McKay
and Nguyen, 2017). The upregulation of eﬄux systems can often be in
unison with other resistance mechanisms for example porin down-
regulation, which may be directly correlated to adverse environmental
Fig. 1. Double epiﬂuorescent staining (DAPI and Rhodamine) of cells (blue)
and horse blood (red) demonstrating organic material and bacteria retained on
a polymer surface following cleaning. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the Web version of this
article.)
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conditions (Martins et al., 2014). There are seven families of eﬄux
pump which are grouped by multiple factors including the energy
source (ATP hydrolysis or ion electrochemical gradient), protein se-
quence homology and overall protein structure. Most of these eﬄux
systems are multidrug resistant (MDR) pumps and can transport a wide
variety of structurally dissimilar antimicrobials out of the cell, however,
substrate speciﬁc systems also exist (Chitsaz and Brown, 2017).
3.6. Persister cells
Persister cells are a phenotypic variant of the wild type cell whose
sole function is survival in hostile conditions so that they can re-
populate the bioﬁlm (Carvalho et al., 2018). This is achieved by a
distinct change in phenotypic state, to one of dormancy (Chihara et al.,
2015). Dormancy reduces the impact of stressors that act on metabo-
lically active cells (e.g. antibiotics) and can lead to a high level of
multidrug resistance and as a result, recalcitrant chronic infections
(Wood, 2016). The surviving population of persister cells act as a re-
servoir of infection, which can repopulate pathogenic bioﬁlms after
antimicrobial treatments (Del Pozo, 2018).
3.7. Heterogenicity of polymicrobial bioﬁlms
The role of the polymicrobial bioﬁlms in the development and
outcome of infections, is still relatively unexplained. However, bioﬁlms
containing multiple co-habiting strains and species could signiﬁcantly
alter the optimal treatment options (Peters et al., 2012). Yurtsev et al.
(2016) used a model system of two strains of E. coli, each producing a
diﬀerent antibiotic deactivating enzyme, to demonstrate that a co-cul-
ture of the two provided a signiﬁcant level of cross-protection to each
organism than was seen in isolated cultures. This adds to growing
evidence to show that polymicrobial bioﬁlms can provide increased
interspecies antimicrobial resistance and virulence (Schlecht et al.,
2015; Zago et al., 2015; Kong et al., 2016). Currently, little is known
about interspecies interactions and their possible eﬀects on bioﬁlm
formation, infection outcome and antimicrobial resistance (Azevedo
et al., 2017a).
4. Current antimicrobial approaches
4.1. Incorporated chemicals
Many strategies, and especially those initially employed for
Fig. 2. SEM images demonstrating the diﬀerent morphologies of bacterial cells
following diﬀerent chemical treatments under conditions of ﬂow.
Fig. 3. Heterogeneity and viability (live cells green, dead cells, red) of a bac-
terial bioﬁlm formed under conditions of ﬂow. (For interpretation of the re-
ferences to colour in this ﬁgure legend, the reader is referred to the Web version
of this article.)
Fig. 4. Bioﬁlm of monoculture cells demonstrating the exopolymeric substance
providing a protective layer.
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reducing microbial adhesion on indwelling medical devices have con-
centrated on the modiﬁcation of traditional antimicrobial surface
technologies. They focused largely on the incorporation of anti-
microbials into a surface coating covering the implant. At the forefront
of this work was the incorporation of antiseptics/biocides into the
polymer matrix of the surface coating to achieve a consistent surface
concentration of active agent (Russell and McDonnell, 2000). These
antimicrobial systems acted by inhibiting bioﬁlm formation through the
prevention of planktonic cell adherence to the implant surface. Unlike
indwelling antimicrobial systems based on antibiotic coatings, many
biocidal systems have a much simpler technical formulation process
and oﬀer less chance of antibiotic resistance development (Bach, 1995).
This ability is in contrast to antibiotics which have more discriminant
target sites, so as to only inhibit the prokaryotic cellular processes and
not interfere with eukaryotic host cells (Poehlsgaard and Douthwaite,
2005). These reasons amongst others, led to a Hygienist Panel Meeting
(2010) recommending an increase in the use of medical antiseptics to
ﬁght infection and especially to provide incorporated antimicrobial
protection (Leaper et al., 2010).
4.1.1. Silver
Originally, the design of antimicrobial implants emphasised cathe-
ters and coatings incorporating silver as the active microbial agent,
often coupled with an organic antiseptic (Schaeﬀer et al., 1988;
Johnson et al., 1990; Liedberg and Lundeberg 1990; Heard et al., 1998;
Schierholz, 1998; Bologna et al., 1999). Schaeﬀer et al. (1988) used a
system of silver oxide coated catheters and trichloroisocyanuric acid
within a drainage bag. The results suggested that patients who received
the silver incorporated catheters had a reduced rate of associated bac-
teriuria. The authors also suggested that antimicrobial containing ca-
theters oﬀered an eﬀective way to reduce catheter-associated bacter-
iuria (Schaeﬀer et al., 1988). Likewise, Liedburg and Lundeburg (1990)
examined a Foley catheter coated with a silver alloy and suggested that
patients who received the silver incorporated catheter were less likely
than patients who received a teﬂonised latex catheter to acquire a ur-
inary tract infection. Heard et al. (1998) examined the eﬃcacy of
central venous catheters coated with a combination of chlorhexidine
and silver sulfadiazine. The results showed a 12% reduction in viable
surface bacteria, but this oﬀered no reduction in the incidence of ca-
theter related bacteraemia. Further, to this, numerous meta-analyses of
results over the last two decades have suggested ﬁrst generation
chlorhexidine-silver sulfadiazine (C-SS) coatings on indwelling cathe-
ters oﬀered a reduced rate of bacteraemia, bacteriuria and infection
occurrence (Casey et al., 2008a; Hockenhull et al., 2008; Ramritu et al.,
2008). There have been numerous studies on the antimicrobial action of
silver (Table 1), and the possibilities of silver used in synergistic anti-
microbial combinations with other materials for example graphene
oxide and carbon nanotubes (Si and Quan, 2017; Whitehead et al.,
2017). It may be possible that such antimicrobial combinations could
be incorporated into catheters for use as biocidal agents.
However, a selection of similar analyses have suggested that ca-
theters incorporating C-SS coatings had no signiﬁcant eﬀectiveness in
reducing infection. Logghe et al. (1997) found this to be the case for C-
SS coated central venous catheters, suggesting the antimicrobial in-
corporation had no eﬀect on the rate of bacteraemia or infection.
However, more positive opinions of C-SS catheters seem to have pre-
vailed since a systematic review by Lai et al. (2016) strongly supported
the C-SS coatings ability to reduce catheter-related blood infections.
The authors of the latter also showed that the clinical setting and pa-
tient's condition played a large part in the overall eﬀectiveness of the
implant. This may oﬀer some insight as to why the numerous studies
have found conﬂicting results.
Other metallic compounds have also been incorporated into poly-
meric biomaterials to provide antimicrobial properties. However, for
use within indwelling medical devices there is a strong bias towards
silver compounds. This may be due to the conception that silver oﬀered
the highest antimicrobial eﬃcacy of all the metals (Silvestry-Rodriguez
et al., 2007). However, there is concern regarding the use of metals as
antimicrobials due to their potential toxicity (Hodgkinson and Petris,
2012). It has also been suggested that combinations of metals may re-
sult in synergistic eﬀects (Vaidya et al., 2018). McLean et al. (1993)
demonstrated that a combined silver-copper coating of catheter mate-
rial (butyl rubber silicon rubber, polyvinylchloride, and Teﬂon) pro-
duced a greater eﬃcacy against P. aeruginosa than a control material or
one with only silver coated surfaces.
4.1.2. Nanoparticle silver
The development of polymers containing micro-dispersed nano-
particles has provided a new method of providing a microbiocidal
concentration of silver across the material surface, whilst controlling
the amounts of leaching so that they remain below human cytotoxic
concentrations (Guggenbichler et al., 1999). Stevens et al. (2009) in-
corporated silver nanoparticles into silicone catheter material and
showed an increased antimicrobial activity and reduced thrombogeni-
city to near zero. Stevens et al. (2011) again showed that a catheter
coating containing silver nanoparticles and sodium heparin could sig-
niﬁcantly reduce the adhesion of multiple S. aureus strains and reduce
thrombogenicity to virtually zero. A clinical trial by Fichtner et al.
(2010) also supported silver nanoparticle impregnation of external
ventricular drainage catheters as they concluded it may reduce the risk
of catheter-related infections in neurosurgical patients.
4.2. Incorporated organic compounds
4.2.1. Chlorhexidine
Although most often used as a topical treatment due to possible
toxicity concerns, the use of organic antiseptics incorporated into in-
dwelling implant is increasingly becoming common (Eltorai et al.,
2016). Chlorhexidine is commonly used in combination with chlorox-
ylenol and especially in combination with silver sulfadiazine. Chlor-
hexidine is a bisbiguanide and possesses broad-spectrum bactericidal
and fungicidal properties (Russell and Path, 1986; Hiom et al., 1992).
However, its activity is pH dependent and is reduced in the presence of
organic matter such as serum. Although the mode of action is not
completely deﬁned, it is considered that initial cell membrane damage
is induced by the cationic chlorhexidine interactions with the anionic
phosphate groups in the bacterial lipid layer, allowing passive diﬀusion
for the biocide to attack the cytoplasmic membrane (Table 1). This
results in the leakage of low molecular weight cellular components and
ultimately cell death (Soﬁyanti et al., 2015).
The eﬃcacy of chlorhexidine as a topical antiseptic is well docu-
mented, but as early as 1982 Lamb and Martin had incorporated
chlorhexidine acetate in to an acrylic prosthesis for the use in the re-
duction of oral Candia albicans infections (Loe and Rindom Schiott,
1970; Hennessey, 1973; Lamb and Martin, 1983; Stalder et al., 1992;
Chlebicki and Safdar, 2007; Nuntnarumit and Sangsuksawang, 2013).
Although chlorhexidine and its derivatives have been used as anti-
microbials, there have been studies that suggest that microorganisms
show both resistance and no resistance to these products (Diehl and
Chapman, 1999; Lear et al., 2006; Riazi and Matthews, 2011). In ad-
dition, chlorhexidine was incorporated into numerous catheter types in
combination with silver sulfadiazine so as to provide a broad-spectrum
antimicrobial action. Subsequently, chlorhexidine was also used as the
single active incorporated into anti-infection polyurethane dressings for
vascular and epidural catheters (Shapiro et al., 1990; Hanazaki et al.,
1999; Garland et al., 2001; Mann et al., 2001; Levy et al., 2005). Ho and
Litton (2006) conducted a meta-analysis of relevant clinical studies
using a chlorhexidine impregnated dressing. The authors concluded
that they provided an eﬀective reduction in bacterial colonisation and
were also associated with a reduction in catheter-related bloodstream
infections. More recently, Kerwat et al. (2015) conﬁrmed this ﬁnding,
reporting signiﬁcantly reduced bacterial colonisation to catheter tip
R. Greenhalgh et al. International Biodeterioration & Biodegradation 136 (2019) 1–14
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and insertion sites of 18% and 33% respectively, when compared with a
control. However, the authors also noted that no reductions in rates of
local infection were observed (Kerwat et al., 2015). A more recent
meta-analysis by Safdar et al. (2014) seemed to conﬁrm the ﬁndings of
Ho and Litton since it was found that chlorhexidine-impregnated
dressings signiﬁcantly reduced the rates of CVC colonisation and ca-
theter related bloodstream infection.
4.2.2. Povidine-iodine (PVPeI)
Povidine-iodine (PVPeI) is a commonly used topical antiseptic in
the healthcare environment (Burks, 1998). As far back as 1985, Mandy
showed treatment with a povidone-iodine-impregnated polyethylene
oxide gel (PVPI-POG) dressing reduced the infection of surgical wounds
when compared with a control (Mandy, 1985). Subsequently, work by
others validated the antimicrobial eﬃcacy and anti-inﬂammatory
properties oﬀered by iodine-containing medical sutures (Singhal et al.,
1991; Polous et al., 1993). However, little further research has been
published. This might be due to success of chlorhexidine (and silver
compounds) as when PVP-I was compared with chlorhexidine gluco-
nate it did not seem to be provide the same reduction in bloodstream
infection when used to disinfect the catheterisation site
(Chaiyakunapruk et al., 2002). The authors further suggested that this
might be due to the interference of organic matter in the biocidal ef-
ﬁcacy of PVP-I coupled with the minimal residual microbial eﬃcacy
oﬀered by PVP-I.
4.2.3. Polyvinylpyrrolidone
Kristinsson et al. (1991) showed a reduction of microbial adherence
and growth on iodine-complexed polyvinylpyrrolidone for up to 5 days.
Polyvinylpyrrolidone coated catheters were commercialised under the
name ‘Hydrocath’. Jansen et al. (1992) investigated commercially
available Hydrocath catheters complexed in polyvinylpyrrolidone and
showed inhibition of S. epidermis adherence for up to 48 h even against
proliferating bacteria in a brain heart infusion media (BHI). Romano
et al. (1993) demonstrated using a mouse model, that sections of Hy-
drocath catheters without a teicoplanin coating developed a relatively
high level of colonisation by S. aureus or S. epidermidis. In addition, it
was suggested that the sections of Hydrocath without teicoplanin
coatings developed surrounding abscesses. The modern Argon Hydro-
cath Assure™ (Argon Critical Care Systems Singapore Pte. Ltd., Singa-
pore) range of catheters utilise both a hydrophilic polyvinylpyrrolidone
coating and antimicrobial Benzalkonium Chloride (BZC) impregnation.
4.2.4. Benzalkonium chloride (BAC)
An early study by Tebbs and Elliott (1993) described the ability of a
BAC impregnated catheter to reduce the in vitro microbial adhesion of
Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and Candida al-
bicans and 4 strains of S. epidermidis in a complex human blood and PBS
media. Subsequently, Moss et al. (2000) examined the implantation of a
polyurethane triple-lumen central venous catheter coated with ben-
zalkonium chloride in 117 patients, compared to a control in 118 pa-
tients. After 12 days the catheters were removed and the results sug-
gested that the catheters coated in BAC signiﬁcantly reduced microbial
Table 1
Biochemical processes and mechanisms of chemical strategies.
Chemical Biochemical process/mechanism Reference
Silver Generation of Reactive Oxygen Species (ROS). ROS, in-turn, cause direct damage to
mitochondrial membrane and hyperoxidation of lipids, proteins and DNA.
Park et al., 2009.
Kim et al., 2011.
Huang et al., 2010
Chlorhexidine Interaction with membrane cardiolipin and phosphatidylethanolamine, disturbing
normal arrangement/integrity of the bilayer structure
Coagulation of cytoplasmic proteins.
Cheung et al., 2012
Hugo and Longworth, 1966; Sheppard et al.,
1997.
Povidine-iodine (PVPeI) The antimicrobial activity of PVP is enhanced by the iodine that causes oxidation of
reactive moieties on cell surfaces and disruption of electron transport.
Kanagalingam et al., 2015
Polyvinylpyrrolidone Poly(vinyl pyrrolidone) (PVP), has a limitation of the lack of a reactive group.
However, molecular analysis (qPCR) has conﬁrmed that it does aﬀect the expression of
genes involved in oxidative stress and in nanoparticle form it possess positive charges
that can target the negative phospholipid surface, directly increasing membrane
permeability leading to disturbance of cell osmotic balance and disruption of
membrane.
Krezovic et al., 2017; Milosavljevic et al.,
2017; Ng et al., 2013
Benzalkonium Chloride (BAC) A quaternary ammonium cation-based disinfectant. Binds to, and disrupts cell
membranes thereby initiating autolysis and the leakage of intracellular constituents.
Ioannou et al., 2007
Triclosan Inhibitition of bacterial fatty acid synthesis by targeting enoyl-[acyl-carrier protein]
reductase
Heath et al., 1999;
Levy et al., 1999
Octenidine Interaction with membrane cardiolipin, disturbing normal arrangement/integrity of
the bilayer structure. Interferes with the enzymatic systems, disturbs cell functions and
leads to the leakage of the plasma membrane.
Hübner et al., 2010
Malhotra et al., 2016
Minocycline Binding to 30S ribosomal subunit, preventing attachment of the aminoacyl tRNA to the
RNA-ribosome complex
Chukwudi, 2016
Rifampin Inhibition of DNA synthesis by targeting bacterial RNA polymerase (RNAP) Hartmann et al., 1967
Gentamicin Binds to h44 of 16S rRNA and binds to H69 of 70s rRNA. Inhibition of ribosomal
translocation.
Moazed and Noller, 1987; Borovinskaya
et al., 2007; Cabañas et al., 1978
Heparin Reduces bacterial adhesion by inducing increased surface hydrophilicity, causing a
highly hydrated interface.
Ruggieri et al., 1987
Poly(ethylene glycol) (PEG) Reduces bacterial adhesion due to increased surface hydrophilicity. Kingshott et al. 2003
Antimicrobial Peptides (AMPs) Cationic molecules - allows their interaction with negatively charged components
present in the bacterial membrane and cell wall. AMPs are also amphipathic allowing
partition into bacterial cell membranes. Evidence of macromolecular synthesis
inhibition, nucleic acid and protein synthesis inhibition, and disruption of cell wall
synthesis.
Mohammad et al., 2015; Papagianni, 2003;
Lehrer et al., 1989; Park et al., 1998a,b
Chitosan [poly-(b-1/4)-2-amino-2-
deoxy-D-glucopyranose]
Binds to teichoic acids within the bacterial cell wall thereby disrupting cell shape
determination and regulation of cell division, ultimately resulting in microbial death.
Raafat et al., 2008
Lactobacillus Derived Biosurfactants Reduce surface tension and interfacial tension, inhibiting the adherence of pathogens
to the surface. Also reduce the adherence capacity of several pathogens themselves
thereby inhibiting bioﬁlm proliferation and formation. Competitive exclusion has also
been demonstrated.
Satpute et al., 2016; Rodrigues et al., 2006;
Walencka et al., 2008; Schachtsiek et al.,
2004
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contamination, when compared with the control (Moss et al., 2000).
Conversely, Jaeger et al. (2001) found that BZC impregnated catheters
showed no signiﬁcant decrease in the incidence of microbial catheter
colonisation or bacteraemia in patients with a high risk of infectious
complications, when compared with a control. Further, the case pre-
sented by Shih et al. (2010) reported the suggested occurrence of
anaphylactic shock induced by the implantation and allergy to a BAC
coated catheter, although this was a seemingly rare case.
4.2.5. Triclosan
Triclosan is a common topical antiseptic and disinfectant used
within the healthcare environment (Regös et al., 1979; Levy, 2000).
The commercial incorporation of triclosan into medical products was
also established with the development of Vicryl Plus® sutures (Barbolt,
2002; Storch et al., 2004; Ford et al., 2005; Edmiston et al., 2006). In
2013, Wang et al. conducted a meta-analysis on the ability of triclosan
coated polyurethane sutures to decrease the development of surgical
site infections. The authors examined 3720 cases and their ﬁnal con-
clusion was that triclosan coated sutures reduced the surgical site in-
fection rate by 30% (Wang et al., 2013). In addition, Hernández-Richter
et al. (2000) used animal models to conﬁrm triclosan incorporated
dacron grafts signiﬁcantly reduced the incidence of prosthesis infection
when compared with a control. Hernández-Richter et al. (2003) also
demonstrated triclosan incorporated vascular grafts oﬀered an anti-
microbial eﬀect against S. aureus when subcutaneously implanted into
an animal model. More recently, Ricco et al. (2012) revealed a pre-
liminary experiment indicating a silver-triclosan incorporating vascular
graft could provide fast acting bactericidal eﬃcacy against MRSA. In
recent years the use of triclosan has been subjected to increased reg-
ulatory scrutiny due to its increasingly ubiquitous use, suspected lack of
eﬃcacy and negative eﬀects through environmental and anthro-
pological accumulation. It has been recorded to have both cytotoxic and
endocrine disruptive properties, as well as a propensity to photo-
degrade into dioxins (Aranami and Readman, 2007; Henry and Fair,
2013). It has been hypothesised that triclosan could also be a carci-
nogen, cause gut and oral microbiome disruption whilst also potentially
being neurotoxic (Dinwiddie et al., 2014; Halden, 2016; Siddique et al.,
2016; Ruszkiewicz et al., 2017). In Europe, this led to the Scientiﬁc
Committee on Consumer Safety removing triclosan from the positive
list of additives and its use in food contact materials became prohibited
(SCCP (Scientiﬁc Committee on Consumer Products) 2011). As it is also
not registered in the framework of the European regulation on biocides,
it is also prohibited from use as a disinfectant in the production of food
or feed. Most recently, in 2017, the FDA ruled that 23 antibacterial
actives, including triclosan, could no longer be recognized as safe and
eﬀective for use in over-the-counter (OTC) health care antiseptic pro-
ducts. This included health care personnel hand washes and rubs, sur-
gical hand scrubs and rubs, and patient antiseptic skin preparations
since it was decided that no additional safety or eﬀectiveness data had
been provided to the FDA (FDA, 2017). Additionally, it should also be
noted that that the change of public opinion, regarding the safety of
triclosan, has led to the decline of manufacturers supporting its inclu-
sion in some of their products.
4.2.6. Octenidine
Octenidine is another potential high impact antimicrobial surface
coating suggested for use by a 2009 Hygienist Panel meeting to help
alleviate the pressure on antibiotic use (Leaper et al., 2010). Octenidine
is thought to act as a cationic surface-active compound, binding to the
anionic groups in the cell membrane causing cell immobilisation and
subsequent bursting (Hübner et al., 2010). Hübner et al. (2010) and
Leaper et al. (2010) both supported the potential of octendine to be-
come an incorporated antimicrobial defence which would help to re-
place a other additives such as chlorhexidine, PVP-I and triclosan.
So far, the development of octenidine incorporated medical pro-
ducts is still in development. However, Kälicke et al. (2006) showed a
biodegradable poly-L-lactide (PLLA) coating incorporating both octe-
nidine and triclosan for use on implants could potentially reduce in-
fection rates by 66% in vivo. This was comparable to a similar antibiotic
coating the authors tested, and led them to the conclusion that such
antiseptic coatings could oﬀer the same level of infection protection as
antibiotic based coatings without the potential for development of re-
sistance (Kälicke et al., 2006). Matl et al. (2009) showed that sutures
incorporating polyglycolic acid (PGA), a biodegradable thermopolymer
polymer, and octenidine showed sustained anti-infection properties,
However, it has been suggested that further investigation to improve
the biocompatibility of such new antimicrobial surfaces needs to be
conducted (Matl et al., 2009). The inclusion of octenidine to poly-
methylmethacrylate (PMMA), has shown a strong antibacterial eﬃcacy
against both S. aureus and P. aeruginosa (Weckbach et al., 2012). A
polymeric dental resin containing octenidine has further been shown to
signiﬁcantly reduced bioﬁlm formation after 3 days and 7 days in situ
(Rupf et al., 2012).
4.3. Antibiotic coatings
The most popular polymers for antibiotic incorporation are PMMA,
poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid), polyethylene
glycol, and poly(D,L)lactide (PDLLA) (Luo et al., 2006). The impreg-
nation, incorporation or coating of many diﬀerent antibiotics has been
examined with varying success however, factors can inﬂuence the ef-
ﬁcacy including biocompatibility, retention of antibiotic activity
through the formulation process (non thermolabile etc.) and the spe-
ciﬁc infectious organisms targeted. For example, the formulation and
physicochemical compatibility between the antibiotics and the poly-
mers has been shown to drastically alter the length and rate of anti-
biotic release (Schierholz et al., 1997). For antibiotic impregnated de-
vices, the antibiotic is usually incorporated into the bulk material of the
device just prior to injection moulding or extrusion.
4.3.1. Minocycline-rifampin
A frequently incorporated antibacterial combination into polymers
is minocycline-rifampin (M-R). Raad et al. (1997) compared the use of
M-R and C-SS polyurethane catheters with the results appearing to
suggest that M-R incorporation had enhanced antimicrobial eﬃcacies.
For example, when incubated into serum, the antimicrobial half-life of
M-R incorporated catheters was 25 days, compared to 3 days demon-
strated by C-SS incorporated catheters and in rabbit models M-R coated
catheters showed a signiﬁcantly greater eﬃcacy in preventing coloni-
sation and infection with S. aureus. Furthermore, M-R coated catheters
showed broad-spectrum eﬃcacy which was signiﬁcantly greater than C-
SS coated catheters when challenged with many diﬀerent strains of
Gram-positive and Gram-negative bacteria or C. albicans. In vivo ex-
periments also revealed that M-R coated catheters were highly eﬃca-
cious in preventing both microbial colonisation and infection (Raad
et al., 1996). Similarly, Hampl et al. (1995) examined the use of ri-
fampin-loaded silicone catheters to reduce the potential infection of
cerebrospinal ﬂuid (CSF) shunts. These catheters provided a bacter-
icidal concentration of rifampin for up to 60 days. Using a rabbit model
inoculated with S. epidermis and S. aureus rifampin-loaded catheters to
signiﬁcantly reduced the incidence of CSF shunt infection from the
main causative organisms (Hampl et al., 1995).
Raad et al. (1997) conducted a randomised, double-blind trial of
tridodecylmethyl-ammonium chloride pre-treated and M-R coated or
untreated, uncoated catheters. This trial consisted of two hundred and
eighty-one hospital patients who required venous catheterisation. The
authors concluded that M-R coated catheters could signiﬁcantly reduce
both microbial colonisation and catheter-related bloodstream infection
as no patients who received the M-R coated catheters developed an
infection (Raad et al., 1997). This was further reinforced by a meta-
analysis of antimicrobial catheters which concluded that minocycline-
rifampin impregnated intravascular catheters were the most successful
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at reducing the development of catheter-related bloodstream infection,
especially when used for less than seven days.
A multiple subsequent meta-analysis by Falagas et al. (2007) and
Casey et al. (2008b) compared control catheters with M-R impregnated
central venous catheters found that they oﬀered a reduced risk of mi-
crobial colonisation and catheter-related bloodstream infection. The
use of rifampin-miconazole impregnated venous catheters was also
found to oﬀer a signiﬁcant decrease in the risk of catheter-related
bloodstream infections (Lorente et al., 2016). Alongside such antibiotic
use in catheters, Hernández-Richter et al. (2003) demonstrated that
rifampin incorporated vascular Dacron graft material provided a sig-
niﬁcant reduction in infection rate, when compared to a control. Ri-
fampin containing products were even found to outperform silver or
triclosan incorporated materials, following subcutaneous implantation
and contamination with S. aureus (Hernández-Richter et al., 2003).
The potential to save an estimated $100 million through the use of
such modiﬁed catheters has been suggested (Pai et al., 2001). Hanna
et al. (2004) conﬁrmed these ﬁnding with long-term study (100 days) of
non-tunnelled silicone catheters impregnated with M-R in three hun-
dred and sixty-ﬁve cancer patients. The results revealed that they were
eﬃcacious and safe in reducing catheter-related bloodstream infections
in cancer patients, however it was acknowledged that there was an
overall low infection rate across the trial (Hanna et al., 2004).
4.3.2. Gentamicin
As early as 1979, Olanoﬀ et al. had incorporated gentamicin into the
silicon rubber of a prosthetic heart valve to successfully reduce infec-
tion in dogs. More recently, the use of gentamicin loaded PDLLA
coatings of indwelling devices has been examined. PDLLA is a biode-
gradable polymer which facilitates the release of gentamicin to protect
the implant surface from microbial colonisation and infection. Lucke
et al. (2003) showed the application of gentamicin loaded PDLLA
coated titanium Kirschner wires to S. aureus contaminated rats sig-
niﬁcantly reduced the level of implant-related infection. This work was
followed by examining gentamicin loaded PDLLA against a systematic
delivery of gentamicin to reduce implant related osteomyelitis in a si-
milar rat model. The authors concluded whilst systematic application of
gentamicin reduced osteomyelitis in 15% of animals, local application
through Kirschner wires coated in gentamicin loaded PDLLA, reduced
bacterial infection by 90% (Lucke et al., 2005). Similarly, Vester et al.
(2010) found that in a rat model a gentamicin loaded PDLLA coating of
titanium implants successfully reduced bacterial adhesion to the im-
plant site and therefore provided a suitable treatment to ﬁght such
infection. These results appear to suggest gentamicin loaded PDLLA
could potentially help signiﬁcantly reduce infection in human im-
plantation.
Although gentamicin and Minocycline-rifampin incorporation ap-
pears to be a valuable option in reducing the microbial colonisation of
indwelling medical devices, other antibiotics have been examined.
Jansen et al. (1992) found that Hydrocath polyvinylpyrrolidone coated
catheters whose surface was loaded with teicoplannin prevented S.
epidermidis colonisation for 48 h in vitro. Similarly, lystostaphin coated
polystyrene and FEP polymer catheters were shown to prevent surface
colonisation and actively kill multiple strains of S. aureus. These ca-
theters also seemed to retain full antimicrobial eﬃcacy even when in-
cubated with human serum which indicated that in vivo usage would
not adversely aﬀect their antimicrobial eﬃcacy (Shah et al., 2004).
Teicoplanin-impregnated silicone knee cement spacers have been
shown to be a highly eﬀective method for eradicating already infected
knee replacements. Twenty ﬁve patients were studied of which twenty
four had been successfully treated with this technique (Buyuk et al.,
2016). Tobramycin has also been prepared in bioresorbable micro-
spheres, using a copolymerisation of 50% lactic and 50% glycolic acid
which when used in rabbit model studies, revealed a signiﬁcant level of
infection prevention when implanted within metal orthopaedic im-
plants infected with S. aureus (Ambrose et al., 2014).
5. Surface modiﬁcation and intrinsic surface antibacterial
strategies
Since the beginning of the twenty-ﬁrst century there has been sig-
niﬁcant interest in the development of implants with chemically or
topographically modiﬁed surfaces, or intrinsic contact-killing or re-
pellent properties. Surfaces that actively disrupt and kill cells on contact
are classiﬁed as antimicrobial. Antifouling materials which oﬀer re-
pellent properties are regarded as anti-biofouling. Bacterial surface at-
tachment occurs though multiple mechanisms including hydrophobic
and electrostatic interactions (Nagel et al., 1996). From a chemical and
physicochemical modiﬁcation perspective, antifouling surfaces usually
focus on imposing three properties to repel microbial attachment; hy-
drophobicity, negative charge or low surface energy.
5.1. Charged surfaces
5.1.1. Heparin
Since the late 1980's modiﬁcation of surfaces by means of heparin
coatings have been shown to reduce bacterial adhesion by inducing
increased surface hydrophilicity, causing a highly hydrated interface.
Ruggieri et al. (1987), demonstrated when catheters of latex, Teﬂon
coated latex and vinyl were ionically coated with a complex of heparin
and tridodecylmethylammonium chloride (TDMAC), bacterial adhesion
was signiﬁcantly reduced. This was especially evident for latex cathe-
ters where bacterial adhesion was reduced to less than 10% compared
with an untreated control. Further, a study by Riedl et al. (2002) sug-
gested that a polyurethane ureteral stents and silicone nephrostomy
tubes with a heparin coating eﬀectively inhibited all bioﬁlm formation
over a six week period. It has been suggested that heparin-coated an-
tibiotic impregnated catheters might be an eﬀective approach to reduce
catheter related bloodstream infections. Investigation into the sy-
nergistic co-impregnation of catheters with silver and heparin have also
shown strong biocidal and anti-thrombogenic properties (Croes et al.,
2011; Stevens et al., 2011).
5.1.2. Poly(ethylene glycol) (PEG)
Immobilised PEG based surface coatings are among the most studied
hydrophilic antifouling coatings. It has been suggested that if a material
can resist the surface adsorption of proteins, the adhesion of bacteria
will be severely limited (Ostuni et al., 2001). However, in practice the
addition of such protein inhibitors, for example PEG coatings, to a wide
range of medical synthetic polymers has shown mixed results in its
ability to reduce bacterial adhesion, be it in either the form of a steric
barrier of polymer brushes or self-assembled monolayers (SAMs). Park
et al. (1998b) demonstrated that PEG modiﬁed polyurethane with ei-
ther a terminal hydroxyl, amino or sulfonate group showed mixed re-
sistance to S. epidermis adhesion, and was dependant on the terminal
group, molecular weight and growth media. Kingshott et al. (2003) also
reported that PEG coated stainless steel could not reduce adhesion of
Pseudomonas sp. when compared with a control. However, a poly
(ethylene terephthalate) (PET)/PEG surface was able to reduce adhe-
sion by up to 4 orders of magnitude for 5 h (Kingshott et al., 2003). A
recent interpretation of results of the bactericidal eﬃcacy of PEG SAMs
led to suggestions by Banerjee et al. (2011) that a protein resistant
surface did not necessarily equate to a bacterial resistant surface. In
addition, another issue is the surface attachment of PEG and therefore
potential surface protein absorption cannot be reduced below a
threshold level since steric forces limit the attachment density (Banerjee
et al., 2011). PEG also oxidises after long periods in complex media,
thus further developments are needed to reduce bacterial adhesion on
indwelling medical devices in the current form (Kane et al., 2003;
Cheng et al., 2008).
5.1.3. Novel surface attached dendrimers and polymer brushes
Functional coatings using polymer brushes have been used to
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covalently secure antimicrobial peptides (AMP's) to a surface. Paris
et al. (2017) demonstrated the use of natural antiadhesive and biocidal
products (hyaluronic acid and nisin) covalently bonded to polyethylene
could reduce S. epidermidis adhesion by 99.8% in vitro. Similarly, Li
et al. (2017) used a thiol-ol reaction to graft two natural antibacterial
polymers (agarose (AG) and quaternized chitosan (QCS)) to a both
polyvinyl ﬂuoride and polyurethane with the aim of reduced bioﬁlm
formation. The AG coating achieved a>2 log reduction against P.
aeruginosa and S. aureus bioﬁlm formation and the QSC reduced surface
associated bacteria by> 95% (Li et al., 2017). Gao et al. (2016) grafted
a compound, consisting of a dodecyl-alkylated quaternary ammonium
and a benzophenone moiety, on to the surface of polyethylene (PE) and
polyvinyl acetate (PVA) samples. Signiﬁcant and rapid eﬃcacy was
noted against S. aureus and E. coli with the surface antimicrobial ac-
tivity being restored simply by the removal of the dead bacteria (Gao
et al., 2016). Although the above ﬁndings were positive, further in vivo
testing must be conducted to fully explore the host environment in-
teractions and biomolecular conditioning with the antimicrobial sur-
faces to fully establish the eﬃcacy of such surfaces.
5.2. Biological and Naturally derived strategies
5.2.1. Antimicrobial peptides (AMPs)
Antimicrobial peptides are the innate defence molecules used by
animals, plants and microorganisms, which have been used as a design
template for large variety of synthetically produced AMPs. AMPs are
most often amphipathic, cationic peptides that oﬀer a broad spectrum
of antimicrobial activity. It has been suggested that AMPs are unlikely
to lead to developed resistance due to their distinctive mechanisms, in
addition, they are highly biocompatible and can modulate the innate
host immune response (Ragland and Criss, 2017; Chin et al., 2018).
Furthermore, in recent years AMPs have displayed signiﬁcant potential
to treat infections caused by multidrug-resistant pathogens
(Mohammad et al., 2015; Riool et al., 2017). Most studies examining
the eﬃcacy of AMPs have focused on titanium surfaces, for the use in
orthopaedic medicine, and most in vivo testing has been performed on
titanium surfaces (Li et al., 2015; Chen et al., 2016; Rai et al., 2016; Ye
et al., 2016; Cheng et al., 2017; Nilebäck et al., 2017; Yu et al., 2017). A
recent study by Yu et al. (2017) highlighted the potential for the in-
tegration of AMP strategies into polymeric medical implants. Yu et al.
(2017) attached AMP E6 via brush coating tethering to a PU catheter
and P. aeruginosa, S. aureus and S. saprophyticus were chosen to chal-
lenge the product in both in vitro and an in vivo mouse urinary infection
model to examine bacterial adherence. The polymer brush and AMP E6
combination demonstrated a signiﬁcant decrease in bacterial adherence
(> 4 log reduction) against all species over the duration of the ex-
periment. A previous study by Lim et al. (2015) had also shown the
proof of concept regarding surface immobilisation of another potent
synthetic antimicrobial peptide, CWR11, on pieces of a silicone coated
Foley catheter via an initial Polydopamine (PD) pre-treatment. The
authors concluded, by using SEM and confocal microscopy analysis,
that the PD-CWR11 treatment signiﬁcantly reduced the attachment and
bioﬁlm formation of E. coli, S. aureus and GFP-P. aeruginosa when
compared with the untreated sample (Lim et al., 2015). Similarly, Li
et al. (2014) conducted experiments using E. coli, S. aureus and C. al-
bicans to challenge two novel AMPs, RK1 and RK2, tethered to the
surface of silicon catheters by allyl glycidyl ether (AGE) polymer bru-
shes. The results of in vitro testing in growth medium, showed sig-
niﬁcant reductions in bioﬁlm formation on both RK1 and RK2 con-
taining samples, when compared with a control (Li et al., 2014).
Additionally, Dutta et al. (2016) highlighted the antimicrobial eﬃcacy
of four AMPs (viz. LL-37, melimine, lactoferricin and Mel-4) when im-
mobilised on Polyhydroxymethacrylate (pHEMA), a common polymer
used for medical applications. The results suggested that pHEMA with
immobilised melamine and LL-37 showed the greatest inhibition of
both P. aeruginosa and S. aureus, with melamine displaying the greatest
eﬃcacy against both organisms (Dutta et al., 2016). Nilebäck et al.
(2017) recently demonstrated another method tethering AMPs by using
biologically active peptides to functionalise a PU surface, amongst
others. The authors used recombinant silk protein assemblies on the
surfaces to form nanoﬁbrillar structures and therefore impart an anti-
microbial eﬀect through the attachment of magainin, an antimicrobial
peptide. Confocal microscopy showed that the combination of poly-
styrene, magainin and silk showed a signiﬁcantly lower bacterial load
than polystyrene or silk and just polystyrene, after 24h and 48h
(Nilebäck et al., 2017). Finally, although surface attached peptides
seemingly have a promising future in implant protection there are still
some developments needed. For example, the antimicrobial activity can
be severely aﬀected by the tethering procedure (Dutta et al., 2016).
Development is also needed to enable production of these surfaces in
order to increase the transition from preliminary research to clinical
trials and commercial products (Riool et al., 2017; Townsend et al.,
2017).
5.2.2. Chitosan [poly-(b-1/4)-2-amino-2-deoxy-D-glucopyranose]
Chitosan is the collective name given to the range of antimicrobial
polymers based on partially or fully deacetylated chitin. Whilst the
exact mode of action is not yet fully understood, it is hypothesised that
the positively charged chitosan interacts with the negatively charged
bacterial cell membrane, leading to leakage of vital intracellular con-
stituents. Chitosan has been demonstrated to possess antibacterial and
antifungal properties against a wide range of microbial species
(Muzzarelli et al., 1990; No et al., 2002; Rabea et al., 2003). The ability
of surfaces coated with chitosan to resist bioﬁlm formation of bacteria
and yeast has also been documented (Carlson et al., 2016). Over a
period of 54 h, synthetic polymers showed reductions in bioﬁlm via-
bility between 95% and 99.9%, when compared to a control against S.
epidermidis, S. aureus, K. pneumoniae, P. aeruginosa and C. albicans. Most
notably, under the same experimental conditions, the coatings con-
taining chlorhexidine did not signiﬁcantly reduce surface-associated
growth, whereas the chitosan coatings recorded over a 99.9% reduction
(Carlson et al., 2016). A pre-infected in vivo central venous catheter
animal model to demonstrate that chitosan coated polyethylene ca-
theters inhibited bioﬁlm formation, whilst signiﬁcantly reducing the
microbial burden when compared with a control over 24 h (Rabea
et al., 2003). Using a in vivo mouse model Corbrado et al. (2013) also
reported the ability of polyurethane catheters coated at sub-inhibitory
concentrations of chitosan to signiﬁcantly reduce bioﬁlm formation of
S. epidermidis and C. albicans, which are two of the major causative
species associated with catheter-related bloodstream infection.
5.2.3. Lactobacillus derived biosurfactants
The use of biosurfactants has also oﬀered a potentially promising
method of reducing the ability of bacteria to form bioﬁlms on indwel-
ling medical devices. For example, biosurfactants isolated from
Lactobacillus fermenti and Lactobacillus rhamnosus were used to im-
pregnate the surface layer of polystyrene samples and demonstrated a
reduction in adhesion of E. coli, K. pneumoniae and P. aeruginosa
(Brzozowski et al., 2011). Similarly, Velraeds et al. (1997) suggested
the development of catheter material incorporating the biosurfactant,
surlactin, which is produced by Lactobacillus acidophilus. However, the
authors did conclude that these were only preliminary results and that
the composition of suspension media and hydrophobicity of both sub-
strata and suspension media, as well as, the speciﬁc pathogens involved
may play a part in their observations (Velraeds et al., 1997).
6. The economics of polymeric implantation
The CDC has previously reported that approximately 250,000 cen-
tral venous catheter (CVC) related bloodstream infection (BSI) cases
occur each year in the USA alone, with the cost attributable to each
infection being between ca. $34,500 – $56,000. This puts the annual
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cost at dealing with CVC-associated BSI patients between $296 million
and $2.3 billion (O'Grady et al., 2011). Similarly in the UK, CAUTIs
were found to account for 65,000–74,000 patients annually and cost ca.
£125 million pounds a year to treat (Buckley et al., 2017).
The estimated usage of medical polymers is set to keep rising with
the 2017 USA market valued at ca. $5 billion and forecasted to rise to
ca. $7 billion by 2020. This trend is also replicated globally with the
2016 global polymers market size estimated to be $20.5 billion and
expect to rise to between ca. $33 billion by 2025 (Grand View Research,
2018). The global market size for only polymer based devices is also
predicted to rise by 8% compound annual growth rate (CAGR) by 2024
(Global Market Insights, 2017; Grand View Research, 2017). Within
this sector, polyether ether ketone (PEEK) and PE, especially ultra-high
molecular weight polyethylene (UHMWPE) are often suggested by re-
searchers and market forecasters to have the greatest market growth.
This market attractiveness is mainly due to the inherent biocompat-
ibility, structural strength, radiolucency, inert nature and commercial
viability of these polymers providing an extensive potential for future
developments across a large range of implant categories (Gunatillake
and Adhikari, 2016; Singh and Chavan, 2016).
Catheters are the most common implant worldwide, with 5 million
CVC's and 30 million urinary catheters being implanted per year, in the
USA alone (Kornbau et al., 2015; Levering et al., 2016). With both
catheters variants identiﬁed as two of leading origins of HAIs, the
economic impacts of catheterisation can often be signiﬁcant (Havard,
2014; Leeson and Webber, 2017). The calculations can be complicated
by how to decide the overall cost of a BSI. Many suggestions have been
proposed, the NHS cost perspective assumes 6 additional days for ICU
patients or 5 for general ward patients (Hockenhull et al., 2008), whilst
in the USA Goudie et al. (2014) found the extended stay could be up to
19 days (Goudie et al., 2014). This discrepancy highlights the problem
of separating the increased hospitalisation due to BSI from the original
condition, as patients who are more ill are more likely to acquire a BSI.
Often quality-adjusted life years (QALYs) are used as an economic in-
dicator, however this can be diﬃcult to calculate for BSIs, due to in-
creased risk of further infection and the problem of how to accurately
determine the relevant timespan to calculate the incremental cost-ef-
fectiveness ratio (ICER). Hockenhull et al. (2008) also proposed the
economic practicality of silver incorporated catheters. The results from
use in the England and Wales National Health Services (NHS) showed a
cost saving per patient receiving a C-SS coated catheter of approxi-
mately £138 in reduced total medical expense. In addition, randomised,
blind clinical trials conducted separately by Ostendorf et al. (2005) and
Brun-Buisson et al. (2004) found a similar reduction in microbial co-
lonisation of catheters and a trend towards lowered infection rates in
patients with a C-SS implant. Lorente et al. (2014) presented a fa-
vourable cost analysis of chlorhexidine-silver sulfadiazine-impregnated
CVCs and suggested, at least in the USA, they would provide a cost and
health beneﬁt over standard CVCs. Ridyard et al. (2017) demonstrated
that antibiotic (rifampicin and minocycline) impregnated CVCs reduced
the occurrence of blood stream infection (BSI) in paediatric intensive
care units (PICUs) in the UK. However, due to the low incidence rate of
BSI in these locations and the increased cost of the antibiotic im-
pregnated CVCs, which on average cost ca. £31–36 extra per unit, their
general application might not currently provide an overall cost-eﬀec-
tive scheme (Ridyard et al., 2017). Harron et al. (2016) used data from
the same controlled trials as Ridyard et al. (2017) and concluded that
antimicrobial impregnated central venous catheters (CVCs) did oﬀer a
reduced-cost alternative to managing the BSI associated with standard
CVCs, even at the low level of incidence presented (Harron et al., 2016).
Kilonzo et al. (2012) suggest that, while the use of nitrofurazone-im-
pregnated catheters may oﬀer value for money to the UK's NHS, silver
alloy-coated catheters were very unlikely to provide a similar beneﬁts.
The authors also noted that, in this situation, the cost saving would
have been modest at, on average, £7 less than a standard catheter over
6 weeks. Thus, it can be demonstrated that the ﬁnancial advantages of
using such modiﬁed systems are not straightforward and it is diﬃcult to
recommend which system might be the best to use.
7. Global standardisation - implant regulations
The development of the antimicrobial technology and consequential
increase in patient wellbeing, is the ultimate goal of such antimicrobial
surface development. A key barrier to market is the cost and time re-
quired to satisfy the individual regulatory standards of each economic
region. A major point of discussion, is the large diﬀerence in regulatory
frameworks between the USA and the EU (Sorenson and Drummond,
2014). Systematic post-market surveillance could be insightful to assess
product safety, and real world capabilities, especially on speciﬁc sub-
sets of patients and circumstances. Currently in the USA and until re-
cently for the EU postmarket, reporting on implants was for the most
part, voluntary (Kramer et al., 2012). There was also further concerns
about the rigorousness of the EU regulatory body Conformité Europé-
enne (CE) due to the increased level of safety alerts and product recalls
being 13% compared to the USA (27%) (Hwang et al., 2016). Fur-
thermore, many of the products recalled in the EU had never been
granted approval in the USA (US Food and Drug Administration, 2012).
In 2017, the EU updated their medical device regulations with the MDR
2017/745 directive. This directive aims to address the problems in post-
market analysis by increasing the legal demand for device traceability
and failure reporting.
8. The need for holistic systematic strategies
Long-term approaches using combination or synergistic strategies
which provide active antimicrobial options could oﬀer great potential
for controlling implant associated infections. However, successful de-
velopment of such antimicrobial systems requires a greater funda-
mental understanding of the phenotypic and genotypic characteristics
of clinically relevant bioﬁlms. This must be harmonised with additional
extrinsic factors, such as improved biocompatibility. Furthermore, im-
plant incorporated techniques must be used in conjunction with
healthcare-wide strategies including preoperative procedures, surgical
sterilisation and appropriate infection control procedures. A rigorous
and practically tested anti-infection protocol must be developed, across
the patient's entire hospital stay.
While the development of new and better anti-infection strategies is
greatly needed, the proper use of developed strategies at all stages of a
patients stay is paramount. Umscheid et al. (2011) identiﬁed this pro-
blem as they estimated 65%–70% of central line associated bloodstream
infection (CLABSIs) and catheter associated urinary tract infections
(CAUTIs) in the USA could be prevented with the proper implementa-
tion of current evidence-based strategies. The implementation of such
systems has the potential to reduce infections and the subsequent costs
of staﬃng and treatments involved, increase patient welfare, reduce
patient morbidity and mortality and thus reduce overall infection as-
sociated costs. Landrigan et al. (2010) found complementary results in a
retrospective patient review in which they estimated more than 75% of
HAIs could have potentially been prevented, providing a potential na-
tional saving, if the trend was consistent across the USA, of ca. $5
billion a year.
Multiple clinicians have tried to address these problems by im-
plementing the use of Corporate performance-improvement methodol-
ogies, such as Lean Six Sigma, which use data-driven quality-im-
provement methodology to standardise processes and reduce associated
costs (Pyzdek and Keller, 2010). Frankel et al. (2005) ﬁrst showed the
beneﬁt of the Six Sigma techniques on reducing CRBSIs, demonstrating
a 650% reduction (from a CRBSI rate of 11 to 1.7 per 1000 catheter
days) in infection rate. Loftus et al. (2015) also implemented the Six
Sigma Deﬁne-Measure-Analyze-Improve-Control (DMAIC) model to
successfully reduce CLABSIs in a neurotrauma intensive care unit. The
authors also highlighted the need for a multidisciplinary approach, the
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necessity for expert guidance and education at all levels. Such a colla-
borative eﬀort may provide a system wide understanding of the stan-
dardised evidence-based protocol. Galiczewski and Shurpin (2017)
showed that even just the act of having an experienced clinician ob-
serve the procedure, and ensure a standardised evidence-based check
list for catheterisation, reduced the incidence of CAUTIs from 2.24 to 0
per 1000 catheter days. To make the most of these approaches, an or-
ganisation wide implementation is often stressed, but this would re-
quire long-term organisational policy and strategic planning initiatives
(Deblois and Lepanto, 2016).
9. Conclusion
To provide a signiﬁcant decrease in HAI prevalence all issues must
be simultaneously addressed, and implemented. This includes further
development and investigation into device incorporated antimicrobial
technologies, reﬁnement and rigorous adherence of aseptic technique
along with continual education and training programmes for relevant
healthcare professionals. The continued rise of global antibiotic re-
sistance only increases the importance of eﬀorts to reduce the instances
of infection. The focus on strategies which prevent pathogenic bioﬁlm
formation may be the key to decreasing serious infection, especially as
the complete eradication of microbes is unrealistic. The generation of
post-market real-world evidence must also be utilised to provide a
complete understanding of eﬃcacy and cost-eﬀectiveness in such en-
vironments.
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